Johnson & Johnson is assuming full responsibility for the manufacturing of a drug substance for its Covid-19 vaccine at Emergent BioSolutions Inc.’s Bayview facility, the company said in a statement.

It will add dedicated leaders for operations and quality, and “significantly” increase the number of manufacturing, quality and technical operations personnel at the site, according to the statement.

• Rail Vikas Nigam Shares Soar 10% on Securing Rs 837 Crore Order 
• IFCI Shares Skyrocket 15% as Board Approves Merger 
• Prakash Industries Shares Surge 7% on Acquiring 30-Year Mining Lease 
• Stocks Under F&O Ban: Gujarat Narmada Valley, Adani Enterprises, Hindustan Copper, and Others 
• Stocks in Focus: Tech Mahindra, Real Estate Stocks, Signature Global, and Others

The company will work closely with the Food and Drug Administration for the emergency use authorization of the specific facility, adding that all its doses so far have met regulatory quality standards. The company said it expects to deliver almost 100 million doses of the Covid-19 vaccine to the US government by the end of May.